Silence Therapeutics (SLN) Equity Average (2020 - 2025)
Silence Therapeutics (SLN) has disclosed Equity Average for 6 consecutive years, with $68.2 million as the latest value for Q4 2025.
- Quarterly Equity Average fell 47.7% to $68.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $68.2 million through Dec 2025, down 47.7% year-over-year, with the annual reading at $98.2 million for FY2025, 25.84% up from the prior year.
- Equity Average hit $68.2 million in Q4 2025 for Silence Therapeutics, down from $84.1 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $149.6 million in Q2 2024 to a low of $11.7 million in Q4 2021.
- Historically, Equity Average has averaged $85.1 million across 5 years, with a median of $89.0 million in 2024.
- Biggest five-year swings in Equity Average: soared 454.13% in 2024 and later crashed 47.7% in 2025.
- Year by year, Equity Average stood at $11.7 million in 2021, then surged by 59.38% to $18.7 million in 2022, then grew by 25.86% to $23.5 million in 2023, then skyrocketed by 454.13% to $130.4 million in 2024, then crashed by 47.7% to $68.2 million in 2025.
- Business Quant data shows Equity Average for SLN at $68.2 million in Q4 2025, $84.1 million in Q3 2025, and $103.4 million in Q2 2025.